
Pfizer and Novo Nordisk are locked in a high-stakes battle to acquire US obesity drug developer Metsera, sending shockwaves through the pharmaceutical industry.
The two giants have submitted competing bids, with Metsera calling Novo's $10 billion offer "superior."